Use of dose–exposure–response relationships in Phase 2 and Phase 3 guselkumab studies to optimize dose selection in psoriasis

Background Guselkumab is an anti‐interleukin‐23 monoclonal antibody for the treatment of moderate‐to‐severe psoriasis. Objective To evaluate the association between dose–response and exposure–response of guselkumab in Phase 2 and Phase 3 studies to optimize dose selection. Methods Serum guselkumab c...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of the European Academy of Dermatology and Venereology 2019-11, Vol.33 (11), p.2082-2086
Hauptverfasser:	Lebwohl, M., Langley, R.G., Zhu, Y., Zhou, H., Song, M., Shen, Y.K., Parnell Lafferty, K., Reich, K.
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - blood Clinical Trials, Phase II as Topic Clinical Trials, Phase III as Topic Dose-Response Relationship, Drug Humans Psoriasis - drug therapy Severity of Illness Index Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!